Skip to main content
TipRanks
Go Ultimate75% OFF

Cytosorbents (CTSO) Stock Statistics & Valuation Metrics

492 Followers

Total Valuation

Cytosorbents has a market cap or net worth of $15.28M. The enterprise value is $37.64M.

Market Cap
$15.28M
Enterprise Value
$37.64M

Share Statistics

Cytosorbents has 3,151,101 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
3,151,101
Owned by Insiders
23.46%
Owned by Institutions
40.79%

Financial Efficiency

Cytosorbents’s return on equity (ROE) is -1.39 and return on invested capital (ROIC) is -38.77%.

Return on Equity (ROE)
-1.39
Return on Assets (ROA)
-0.19
Return on Invested Capital (ROIC)
-38.77%
Return on Capital Employed (ROCE)
-0.41
Revenue Per Employee
287.31K
Profits Per Employee
-63.55K
Employee Count
129
Asset Turnover
0.84
Inventory Turnover
2.00

Valuation Ratios

The current PE Ratio of Cytosorbents is -0.92. Cytosorbents’s PEG ratio is 0.01.

PE Ratio
-0.92
PS Ratio
0.41
PB Ratio
-6.72
Price to FCF
-1.91
Price to Operating Cash Flow
-1.94
PEG Ratio
0.01

Income Statement

In the last 12 months, Cytosorbents had revenue of 37.06M and earned -8.20M in profits. Earnings per share was -2.60.

Revenue
37.06M
Gross Profit
26.49M
Operating Income
-14.24M
Pretax Income
-8.60M
Net Income
-8.20M
EBITDA
-4.36M
Earnings Per Share (EPS)
-2.60

Cash Flow

In the last 12 months, operating cash flow was -8.00M and capital expenditures -118,883, giving a free cash flow of -8.12M billion.

Operating Cash Flow
-8.00M
Free Cash Flow
-8.12M
Free Cash Flow per Share
-2.58

Dividends & Yields

Cytosorbents pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-52.04%
Earnings Yield
-108.35%

Stock Price Statistics

Beta
0.86
52-Week Price Change
-63.26%
50-Day Moving Average
4.88
200-Day Moving Average
8.95
Relative Strength Index (RSI)
49.54
Average Volume (3m)
36.05K

Important Dates

Cytosorbents upcoming earnings date is Mar 09, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 12, 2026
Next Earnings Date
Mar 09, 2027
Ex-Dividend Date
―

Financial Position

Cytosorbents as a current ratio of 2.13, with Debt / Equity ratio of 493.16%

Current Ratio
2.13
Quick Ratio
1.58
Debt to Market Cap
0.42
Net Debt to EBITDA
-5.25
Interest Coverage Ratio
-5.45

Taxes

In the past 12 months, Cytosorbents has paid -401.00K in taxes.

Income Tax
-401.00K
Effective Tax Rate
0.05

Enterprise Valuation

Cytosorbents EV to EBITDA ratio is -3.40, with an EV/FCF ratio of -5.05.

EV to Sales
1.09
EV to EBITDA
-3.40
EV to Free Cash Flow
-5.05
EV to Operating Cash Flow
-5.12

Balance Sheet

Cytosorbents has $4.21M in cash and marketable securities with $29.57M in debt, giving a net cash position of -$25.37M billion.

Cash & Marketable Securities
$4.21M
Total Debt
$29.57M
Net Cash
-$25.37M
Net Cash Per Share
-$8.05
Tangible Book Value Per Share
-$1.62

Margins

Gross margin is 72.91%, with operating margin of -28.63%, and net profit margin of -45.05%.

Gross Margin
72.91%
Operating Margin
-28.63%
Pretax Margin
-45.05%
Net Profit Margin
-45.05%
EBITDA Margin
-32.12%
EBIT Margin
-36.08%

Analyst Forecast

The average price target for Cytosorbents is $9.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
$9.50
Price Target Upside
95.88% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
9.04%
EPS Growth Forecast
-43.07%

Scores

Smart Score
―
AI Score
49